Canada markets closed

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4400-0.0100 (-0.69%)
At close: 04:00PM EDT
1.4000 -0.04 (-2.78%)
After hours: 07:59PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

    Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program designType B meeting scheduled with FDA; dialogue ongoing with EMA for development in severe COVID-19 JENA, Germany, June 29, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, pr

  • GlobeNewswire

    InflaRx to Present at the H.C. Wainwright Global Investment Conference

    JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H.C. Wainwright Global Investment Conference. The hybrid conference will be held in person in Miami, Florida and virtually from May 23rd to May 26th. InflaRx will present in person on Wednesday, May 25th at 10:30 AM EDT /

  • GlobeNewswire

    InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update

    Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities already underwayFinal data from Phase IIa open-label study in patients with pyoderma gangrenosum presented at 2022 AAD Annual Meeting; end-of-Phase II meeting with FDA scheduled for mid-2022In Phase II trial in cutaneous squamous cell carcinoma, second dosing cohort of combination arm started; enrollment